comparemela.com
Home
Live Updates
ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study : comparemela.com
ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study
ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.
Related Keywords
Toronto
,
Ontario
,
Canada
,
United States
,
Chicago
,
Illinois
,
American
,
America
,
Sumantak Pal
,
Sumanta Pal
,
American Society Of Clinical Oncology
,
Twitter
,
Department Of Medical Oncology
,
Society Of Urologic Oncology
,
University Of Toronto
,
Therapeutics Research
,
City Of Hope Comprehensive Cancer Center
,
Clinical Oncology
,
Annual Meeting
,
South America
,
North America
,
Medical Oncology
,
Hope Comprehensive Cancer Center
,
Rashid Sayyid
,
Urologic Oncology
,
Clinical Fellow
,
comparemela.com © 2020. All Rights Reserved.